IL1B and heart failure: Supporting the IL-1 pathway hypothesis, the VCUART3 trial demonstrated that anakinra, a recombinant IL-1 receptor antagonist, significantly reduced systemic inflammatory response and lowered the incidence of new-onset heart failure and hospitalization for heart failure in STEMI patients.32